Genetics, Pathophysiology, and Current Challenges in Von Hippel–Lindau Disease Therapeutics
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
This review article focuses on von Hippel–Lindau (VHL) disease, a rare genetic disorder characterized by the development of tumors and cysts throughout the body. It discusses the following aspects of the disease. Genetics: VHL disease is caused by mutations in the VHL tumor suppressor gene located on chromosome 3. These mutations can be inherited or occur spontaneously. This article details the different types of mutations and their associated clinical features. Pathophysiology: The underlying cause of VHL disease is the loss of function of the VHL protein (pVHL). This protein normally regulates hypoxia-inducible factors (HIFs), which are involved in cell growth and survival. When pVHL is dysfunctional, HIF levels become elevated, leading to uncontrolled cell growth and tumor formation. Clinical Manifestations: VHL disease can affect various organs, including the brain, spinal cord, retina, kidneys, pancreas, and adrenal glands. Symptoms depend on the location and size of the tumors. Diagnosis: Diagnosis of VHL disease involves a combination of clinical criteria, imaging studies, and genetic testing. Treatment: Treatment options for VHL disease depend on the type and location of the tumors. Surgery is the mainstay of treatment, but other options like radiation therapy may also be used. Challenges: This article highlights the challenges in VHL disease management, including the lack of effective therapies for some tumor types and the need for better methods to monitor disease progression. In conclusion, we emphasize the importance of ongoing research to develop new and improved treatments for VHL disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2015.30 · Cited by 32,594 · cited 1×
“To establish a definitive diagnosis, genetic testing to identify pathogenic variants in the VHL gene is essential [10–13] (Richards et al., 2015).”
BackgroundHIF-1α pathway: role, regulation and intervention for cancer therapy
Masoud, G. N., & Li, W. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.05.007 · Cited by 1,871 · cited 1×
“Transcriptional Regulation: Activated AKT can also enhance the transcription of HIF1 α by promoting its translation and increasing its mRNA levels, further contributing to its accumulation and activity in cancer cells [36].”
BackgroundMutations of the VHL tumour suppressor gene in renal carcinoma
Gnarra, J. R., Tory, K., Weng, Y., Schmidt, L., Wei, M. H., Li, H., Latif, F., Liu, S., Chen, F., Duh, F.-M., et al. (1994) · Nature Genetics · doi:10.1038/ng0594-85 · Cited by 1,730 · cited 3×
“…[70,74] p.Tyr112His [55,86] von Hippel–Lindau syndrome Type 2 and Type 2B p.Arg161Gly [74,87] von Hippel–Lindau syndrome Type 2, Type 2A, and Type 2B p.Thr157Ile [54,71,73] von Hippel–Lindau syndrome Type 2A and Type 2B p.Ala149Ser [88,89] Furthermore, Nordstrom-O’Brien reports a mutation…”
BackgroundInfluentialBrugarolas, J., Lei, K., Hurley, R. L., Manning, B. D., Reiling, J. H., Hafen, E., Witters, L. A., Ellisen, L. W., & Kaelin, W. G. (2004) · Genes & Development · doi:10.1101/gad.1256804 · Cited by 1,384 · cited 1×
“To date, there is still no adequate model to study the CNS and retinal heman-gioblastomas.”
BackgroundEma, M., Taya, S., Yokotani, N., Sogawa, K., Matsuda, Y., & Fujii-Kuriyama, Y. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4273 · Cited by 1,016 · cited 1×
“The consequences of this up-regulation include transcriptional activation of genes containing hypoxia-responsive elements [32,33].”
BackgroundMolecular basis of the VHL hereditary cancer syndrome
Kaelin, W. G. (2002) · Nature Reviews Cancer · doi:10.1038/nrc885 · Cited by 865
Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL
Hon, W.-C., Wilson, M. I., Harlos, K., Claridge, T. D. W., Schofield, C. J., Pugh, C. W., Maxwell, P. H., Ratcliffe, P. J., Stuart, D. I., & Jones, E. Y. (2002) · Nature · doi:10.1038/nature00767 · Cited by 751 · cited 1×
“, the regulation of mTORC1 involves the protein regulated in”
BackgroundInhibition of HIF2α Is Sufficient to Suppress pVHL-Defective Tumor Growth
Kondo, K., Kim, W. Y., Lechpammer, M., & Kaelin, W. G. (2003) · PLoS Biology · doi:10.1371/journal.pbio.0000083 · Cited by 611
Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo
Rankin, E. B., Biju, M. P., Liu, Q., Unger, T. L., Rha, J., Johnson, R. S., Simon, M. C., Keith, B., & Haase, V. H. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30117 · Cited by 596 · cited 1×
“The consequences of this up-regulation include transcriptional activation of genes containing hypoxia-responsive elements [32,33].”
BackgroundKrieg, M., Haas, R., Brauch, H., Acker, T., Flamme, I., & Plate, K. H. (2000) · Oncogene · doi:10.1038/sj.onc.1203938 · Cited by 396 · cited 1×
“Tumorigenesis in VHL syndrome is linked to the loss of function of the VHL tumor suppressor protein in cell differentiation [29] where hypoxia-inducible factors (HIF1 and HIF2) are activated and accumulate in the cell [30,31].”
Background
Research works printed but not linked: 171
- Latif, 1993, Identification of the von Hippel-Lindau disease tumor suppressor gene, Science, 260, 1317, 10.1126/science.8493574 · DOI · Paper page
- Hong, B., Ma, K., Zhou, J., Zhang, J., Wang, J., Liu, S., Zhang, Z., Cai, L., Zhang, N., and Gong, K. (2019). Frequent Mutations of VHL Gene and the Clinical Phenotypes in the Largest Chinese Cohort with Von Hippel-Lindau Disease. Front. Genet., 10. · doi:10.3389/fgene.2019.00867
- Lonser, 2003, von Hippel-Lindau disease, Lancet, 361, 2059, 10.1016/S0140-6736(03)13643-4 · DOI · Paper page
- McMahon, 2016, Von Hippel-Lindau Disease, J. Pediatr. Genet., 5, 116, 10.1055/s-0036-1579757 · DOI
- Rebelo, 2021, Pheochromocytomas and paragangliomas in von Hippel-Lindau disease: Not a needle in a haystack, Endocr. Connect., 10, R293, 10.1530/EC-21-0294 · DOI
- Clark, 2009, The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy, Kidney Int., 76, 939, 10.1038/ki.2009.296 · DOI
- Ohh, 2022, Hypoxia-inducible factor underlies von Hippel-Lindau disease stigmata, eLife, 11, e80774, 10.7554/eLife.80774 · DOI
- Haase, 2006, The VHL/HIF oxygen-sensing pathway and its relevance to kidney disease, Kidney Int., 69, 1302, 10.1038/sj.ki.5000221 · DOI · Paper page
- Tamura, 2023, Variant spectrum of von Hippel-Lindau disease and its genomic heterogeneity in Japan, Hum. Mol. Genet., 32, 2046, 10.1093/hmg/ddad039 · DOI · Paper page
- Horton, 2022, Universal Germline Panel Testing for Individuals with Pheochromocytoma and Paraganglioma Produces High Diagnostic Yield, J. Clin. Endocrinol. Metab., 107, e1917, 10.1210/clinem/dgac014 · DOI
- Oldfield, 2022, VHL mosaicism: The added value of multi-tissue analysis, NPJ Genom. Med., 7, 21, 10.1038/s41525-022-00291-3 · doi:10.1038/s41525-022-00291-3
- Varshney, 2017, A Review of Von Hippel-Lindau Syndrome, J. Kidney Cancer VHL, 4, 20, 10.15586/jkcvhl.2017.88 · DOI · Paper page
- Choyke, 1995, von Hippel-Lindau disease: Genetic, clinical, and imaging features, Radiology, 194, 629, 10.1148/radiology.194.3.7862955 · DOI · Paper page
- Melmon, 1964, Lindau’s Disease. Review of the Literature and Study of a Large Kindred, Am. J. Med., 36, 595, 10.1016/0002-9343(64)90107-X · doi:10.1016/0002-9343(64)90107-x
- Seizinger, 1988, Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma, Nature, 332, 268, 10.1038/332268a0 · DOI · Paper page
- Gossage, 2015, VHL, the story of a tumour suppressor gene, Nat. Rev. Cancer, 15, 55, 10.1038/nrc3844 · DOI · Paper page
- Tanimoto, 2000, Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein, EMBO J., 19, 4298, 10.1093/emboj/19.16.4298 · DOI · Paper page
- Richards, 1996, Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis, Hum. Mol. Genet., 5, 639, 10.1093/hmg/5.5.639 · DOI
- Knudson, 1971, Mutation and cancer: Statistical study of retinoblastoma, Proc. Natl. Acad. Sci. USA, 68, 820, 10.1073/pnas.68.4.820 · DOI · Paper page
- Glasker, 2001, Reconsideration of biallelic inactivation of the VHL tumour suppressor gene in hemangioblastomas of the central nervous system, J. Neurol. Neurosurg. Psychiatry, 70, 644, 10.1136/jnnp.70.5.644 · DOI
- Glasker, 2006, Second hit deletion size in von Hippel-Lindau disease, Ann. Neurol., 59, 105, 10.1002/ana.20704 · doi:10.1002/ana.20704
- Maddock, 1996, A genetic register for von Hippel-Lindau disease, J. Med. Genet., 33, 120, 10.1136/jmg.33.2.120 · DOI · Paper page
- Evans, 2010, Birth incidence and prevalence of tumor-prone syndromes: Estimates from a UK family genetic register service, Am. J. Med. Genet. A, 152A, 327, 10.1002/ajmg.a.33139 · DOI · Paper page
- Maher, 1991, Von Hippel-Lindau disease: A genetic study, J. Med. Genet., 28, 443, 10.1136/jmg.28.7.443 · DOI · Paper page
- Neumann, 1991, Clustering of features of von Hippel-Lindau syndrome: Evidence for a complex genetic locus, Lancet, 337, 1052, 10.1016/0140-6736(91)91705-Y · DOI · Paper page
- Binderup, 2017, Prevalence, birth incidence, and penetrance of von Hippel-Lindau disease (vHL) in Denmark, Eur. J. Hum. Genet., 25, 301, 10.1038/ejhg.2016.173 · DOI
- Haase, 2005, The VHL tumor suppressor in development and disease: Functional studies in mice by conditional gene targeting, Semin. Cell Dev. Biol., 16, 564, 10.1016/j.semcdb.2005.03.006 · DOI
- Iliopoulos, 1996, Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein, Proc. Natl. Acad. Sci. USA, 93, 10595, 10.1073/pnas.93.20.10595 · DOI · Paper page
- Tian, 2023, PI3K/AKT signaling activates HIF1alpha to modulate the biological effects of invasive breast cancer with microcalcification, NPJ Breast Cancer, 9, 93, 10.1038/s41523-023-00598-z · DOI
- Bae, 2024, Hypoxia, oxidative stress, and the interplay of HIFs and NRF2 signaling in cancer, Exp. Mol. Med., 56, 501, 10.1038/s12276-024-01180-8 · DOI · Paper page
- Chen, C.Y., Chen, J., He, L., and Stiles, B.L. (2018). PTEN: Tumor Suppressor and Metabolic Regulator. Front. Endocrinol., 9. · DOI · Paper page
- Singh, 2002, p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas, Genes. Dev., 16, 984, 10.1101/gad.973602 · DOI · Paper page
- Farhan, 2017, FOXO Signaling Pathways as Therapeutic Targets in Cancer, Int. J. Biol. Sci., 13, 815, 10.7150/ijbs.20052 · DOI · Paper page
- Vortmeyer, 2013, Nervous system involvement in von Hippel-Lindau disease: Pathology and mechanisms, Acta Neuropathol., 125, 333, 10.1007/s00401-013-1091-z · DOI
- Albanyan, 2019, Characterization of VHL promoter variants in patients suspected of Von Hippel-Lindau disease, Eur. J. Med. Genet., 62, 177, 10.1016/j.ejmg.2018.07.006 · DOI
- Hsieh, 2018, Chromosome 3p Loss-Orchestrated VHL, HIF, and Epigenetic Deregulation in Clear Cell Renal Cell Carcinoma, J. Clin. Oncol., 36, 3533, 10.1200/JCO.2018.79.2549 · DOI · Paper page
- Liu, Z., Zhou, J., Li, L., Yi, Z., Lu, R., Li, C., and Gong, K. (2020). Intronic mutation of the VHL gene associated with central nervous system hemangioblastomas in two Chinese families with Von Hippel-Lindau disease: Case report. BMC Med. Genet., 21. · DOI
- Peng, S., Zhang, J., Tan, X., Huang, Y., Xu, J., Silk, N., Zhang, D., Liu, Q., and Jiang, J. (2020). The VHL/HIF Axis in the Development and Treatment of Pheochromocytoma/Paraganglioma. Front. Endocrinol., 11. · DOI
- Tarade, 2020, The long form of pVHL is artifactually modified by serine protease inhibitor AEBSF, Protein Sci., 29, 1843, 10.1002/pro.3898 · DOI
- Buffet, 2020, Germline mutations in the new E1’ cryptic exon of the VHL gene in patients with tumours of von Hippel-Lindau disease spectrum or with paraganglioma, J. Med. Genet., 57, 752, 10.1136/jmedgenet-2019-106519 · DOI
- Xie, 2020, Novel genetic characterisation and phenotype correlation in von Hippel-Lindau (VHL) disease based on the Elongin C binding site: A large retrospective study, J. Med. Genet., 57, 744, 10.1136/jmedgenet-2019-106336 · DOI
- Reich, 2021, Genotype-phenotype correlation in von Hippel-Lindau disease, Acta Ophthalmol., 99, e1492, 10.1111/aos.14843 · doi:10.1111/aos.14843
- Sluiter, 2019, The incidence of consecutive manifestations in Von Hippel-Lindau disease, Fam. Cancer, 18, 369, 10.1007/s10689-019-00131-x · DOI
- Vocke, 2021, Comprehensive characterization of Alu-mediated breakpoints in germline VHL gene deletions and rearrangements in patients from 71 VHL families, Hum. Mutat., 42, 520, 10.1002/humu.24194 · doi:10.1002/humu.24194
- Cybulski, 2002, Germline mutations in the von Hippel-Lindau (VHL) gene in patients from Poland: Disease presentation in patients with deletions of the entire VHL gene, J. Med. Genet., 39, E38, 10.1136/jmg.39.7.e38 · DOI
- Tabaro, F., Minervini, G., Sundus, F., Quaglia, F., Leonardi, E., Piovesan, D., and Tosatto, S.C. (2016). VHLdb: A database of von Hippel-Lindau protein interactors and mutations. Sci. Rep., 6. · DOI
- Ong, 2007, Genotype-phenotype correlations in von Hippel-Lindau disease, Hum. Mutat., 28, 143, 10.1002/humu.20385 · DOI · Paper page
- Zbar, 1996, Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan, Hum. Mutat., 8, 348, 10.1002/(SICI)1098-1004(1996)8:4<348::AID-HUMU8>3.0.CO;2-3 · DOI · Paper page
- Chen, 1995, Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: Correlations with phenotype, Hum. Mutat., 5, 66, 10.1002/humu.1380050109 · DOI · Paper page
- Kanno, 1996, Molecular genetic diagnosis of von Hippel-Lindau disease: Analysis of five Japanese families, Jpn. J. Cancer Res., 87, 423, 10.1111/j.1349-7006.1996.tb00240.x · doi:10.1111/j.1349-7006.1996.tb00240.x
- Moore, 2000, Identification of a novel mutation (c279delC) and a polymorphism (c291C>G) in the von Hippel-Lindau gene in Italian patients, Hum. Mutat., 15, 582, 10.1002/1098-1004(200006)15:6<582::AID-HUMU18>3.0.CO;2-P · doi:10.1002/1098-1004(200006)15:6<582::aid-humu18>3.0.co;2-p
- Crossey, 1994, Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype, Hum. Mol. Genet., 3, 1303, 10.1093/hmg/3.8.1303 · DOI · Paper page
- Stolle, 1998, Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene, Hum. Mutat., 12, 417, 10.1002/(SICI)1098-1004(1998)12:6<417::AID-HUMU8>3.0.CO;2-K · DOI · Paper page
- Rechsteiner, 2011, VHL gene mutations and their effects on hypoxia inducible factor HIFalpha: Identification of potential driver and passenger mutations, Cancer Res., 71, 5500, 10.1158/0008-5472.CAN-11-0757 · DOI · Paper page
- Bravo, 2004, Genetic characterization and structural analysis of VHL Spanish families to define genotype-phenotype correlations, Hum. Mutat., 23, 160, 10.1002/humu.10309 · DOI
- Webster, 1999, Clinical characteristics of ocular angiomatosis in von Hippel-Lindau disease and correlation with germline mutation, Arch. Ophthalmol., 117, 371, 10.1001/archopht.117.3.371 · doi:10.1001/archopht.117.3.371
- van Houwelingen, K.P., van Dijk, B.A., Hulsbergen-van de Kaa, C.A., Schouten, L.J., Gorissen, H.J., Schalken, J.A., van den Brandt, P.A., and Oosterwijk, E. (2005). Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: Results from The Netherlands cohort study. BMC Cancer, 5. · DOI
- Rocha, 2003, High frequency of novel germline mutations in the VHL gene in the heterogeneous population of Brazil, J. Med. Genet., 40, e31, 10.1136/jmg.40.3.e31 · DOI
- Lolkema, 2010, Genetic analysis of von Hippel-Lindau disease, Hum. Mutat., 31, 521
- Cho, 2009, Improved detection of germline mutations in Korean VHL patients by multiple ligation-dependent probe amplification analysis, J. Korean Med. Sci., 24, 77, 10.3346/jkms.2009.24.1.77 · DOI
- Wu, 2012, Family history of von Hippel-Lindau disease was uncommon in Chinese patients: Suggesting the higher frequency of de novo mutations in VHL gene in these patients, J. Hum. Genet., 57, 238, 10.1038/jhg.2012.10 · DOI
- Kang, 2005, Three novel VHL germline mutations in Korean patients with von Hippel-Lindau disease and pheochromocytomas, Oncol. Rep., 14, 879
- Clinical Research Group for VHL in Japan (1995). Germline mutations in the von Hippel-Lindau disease (VHL) gene in Japanese VHL. Hum. Mol. Genet., 4, 2233–2237. · doi:10.1093/hmg/4.12.2233
- Neumann, 2002, Germ-line mutations in nonsyndromic pheochromocytoma, N. Engl. J. Med., 346, 1459, 10.1056/NEJMoa020152 · DOI · Paper page
- Yoshida, 2000, Germ-line mutation analysis in patients with von Hippel-Lindau disease in Japan: An extended study of 77 families, Jpn. J. Cancer Res., 91, 204, 10.1111/j.1349-7006.2000.tb00933.x · DOI
- Olschwang, 1998, Germline mutation profile of the VHL gene in von Hippel-Lindau disease and in sporadic hemangioblastoma, Hum. Mutat., 12, 424, 10.1002/(SICI)1098-1004(1998)12:6<424::AID-HUMU9>3.0.CO;2-H · DOI · Paper page
- Glavac, 1996, Mutations in the VHL tumor suppressor gene and associated lesions in families with von Hippel-Lindau disease from central Europe, Hum. Genet., 98, 271, 10.1007/s004390050206 · DOI
- Maher, 1996, Phenotypic expression in von Hippel-Lindau disease: Correlations with germline VHL gene mutations, J. Med. Genet., 33, 328, 10.1136/jmg.33.4.328 · DOI · Paper page
- Vortmeyer, 1997, Allelic deletion and mutation of the von Hippel-Lindau (VHL) tumor suppressor gene in pancreatic microcystic adenomas, Am. J. Pathol., 151, 951
- Bauters, 2003, Hereditary phaeochromocytomas and paragangliomas: A study of five susceptibility genes, J. Med. Genet., 40, e75, 10.1136/jmg.40.6.e75 · DOI
- Ritter, 1996, Isolated familial pheochromocytoma as a variant of von Hippel-Lindau disease, J. Clin. Endocrinol. Metab., 81, 1035
- Hes, 2007, Frequency of Von Hippel-Lindau germline mutations in classic and non-classic Von Hippel-Lindau disease identified by DNA sequencing, Southern blot analysis and multiplex ligation-dependent probe amplification, Clin. Genet., 72, 122, 10.1111/j.1399-0004.2007.00827.x · DOI
- Wang, 2014, Higher prevalence of novel mutations in VHL gene in Chinese Von Hippel-Lindau disease patients, Urology, 83, 675.e1, 10.1016/j.urology.2013.09.069 · DOI
- Garcia, 1997, Molecular diagnosis of von Hippel-Lindau disease in a kindred with a predominance of familial phaeochromocytoma, Clin. Endocrinol., 46, 359, 10.1046/j.1365-2265.1997.00149.x · doi:10.1046/j.1365-2265.1997.00149.x
- Lee, J.S., Lee, J.H., Lee, K.E., Kim, J.H., Hong, J.M., Ra, E.K., Seo, S.H., Lee, S.J., Kim, M.J., and Park, S.S. (2016). Genotype-phenotype analysis of von Hippel-Lindau syndrome in Korean families: HIF-alpha binding site missense mutations elevate age-specific risk for CNS hemangioblastoma. BMC Med. Genet., 17. · DOI
- Crossey, 1995, Molecular genetic diagnosis of von Hippel-Lindau disease in familial phaeochromocytoma, J. Med. Genet., 32, 885, 10.1136/jmg.32.11.885 · DOI · Paper page
- Gross, 1996, Familial pheochromocytoma associated with a novel mutation in the von Hippel-Lindau gene, J. Clin. Endocrinol. Metab., 81, 147
- Bar, 1997, Sporadic phaeochromocytomas are rarely associated with germline mutations in the von Hippel-Lindau and RET genes, Clin. Endocrinol., 47, 707, 10.1046/j.1365-2265.1997.3251150.x · DOI · Paper page
- Tisherman, 1962, Familial pheochromocytoma, JAMA, 182, 152, 10.1001/jama.1962.03050410048010 · doi:10.1001/jama.1962.03050410048010
- Murgia, 2000, Somatic mosaicism in von Hippel-Lindau Disease, Hum. Mutat., 15, 114, 10.1002/(SICI)1098-1004(200001)15:1<114::AID-HUMU20>3.0.CO;2-7 · DOI
- Mete, 2014, Clinical presentation of Von Hippel Lindau syndrome type 2B associated with VHL p.A149S mutation in a large Turkish family, Endocrine, 45, 128, 10.1007/s12020-013-9982-2 · doi:10.1007/s12020-013-9982-2
- Atuk, 1998, Pheochromocytoma in von Hippel-Lindau disease: Clinical presentation and mutation analysis in a large, multigenerational kindred, J. Clin. Endocrinol. Metab., 83, 117
- Brookes, 2013, Diagnostic genetics at a distance: Von hippel-lindau disease and a novel mutation, Genet. Res. Int., 2013, 189196
- Ganeshan, 2018, Tumors in von Hippel-Lindau Syndrome: From Head to Toe-Comprehensive State-of-the-Art Review, Radiographics, 38, 849, 10.1148/rg.2018170156 · DOI
- Chittiboina, 2015, Von Hippel-Lindau disease, Handb. Clin. Neurol., 132, 139, 10.1016/B978-0-444-62702-5.00010-X · DOI · Paper page
- Qiu, J., Zhang, K., Ma, K., Zhou, J., Gong, Y., Cai, L., and Gong, K. (2020). The Genotype-Phenotype Association of Von Hipple Lindau Disease Based on Mutation Locations: A Retrospective Study of 577 Cases in a Chinese Population. Front. Genet., 11. · DOI
- Stebbins, 1999, Structure of the VHL-ElonginC-ElonginB complex: Implications for VHL tumor suppressor function, Science, 284, 455, 10.1126/science.284.5413.455 · DOI · Paper page
- Domene, 2012, Effects of point mutations in pVHL on the binding of HIF-1alpha, Proteins, 80, 733, 10.1002/prot.23230 · DOI
- Razafinjatovo, C., Bihr, S., Mischo, A., Vogl, U., Schmidinger, M., Moch, H., and Schraml, P. (2016). Characterization of VHL missense mutations in sporadic clear cell renal cell carcinoma: Hotspots, affected binding domains, functional impact on pVHL and therapeutic relevance. BMC Cancer, 16. · DOI
- Zhou, 2004, Tumor suppressor von Hippel-Lindau (VHL) stabilization of Jade-1 protein occurs through plant homeodomains and is VHL mutation dependent, Cancer Res., 64, 1278, 10.1158/0008-5472.CAN-03-0884 · DOI · Paper page
- Cervio, 2017, Surgical treatment of cerebellar hemangioblastomas, Surg. Neurol. Int., 8, 163, 10.4103/sni.sni_490_16 · doi:10.4103/sni.sni_490_16
- Klingler, 2020, Hemangioblastoma and von Hippel-Lindau disease: Genetic background, spectrum of disease, and neurosurgical treatment, Childs Nerv. Syst., 36, 2537, 10.1007/s00381-020-04712-5 · doi:10.1007/s00381-020-04712-5
- Karimi, 2020, Von Hippel-Lindau Disease and the Eye, J. Ophthalmic Vis. Res., 15, 78
- Singh, 2001, von Hippel-Lindau disease, Surv. Ophthalmol., 46, 117, 10.1016/S0039-6257(01)00245-4 · DOI · Paper page
- Lin, 2020, Clinical diagnosis, treatment and screening of the VHL gene in three von Hippel-Lindau disease pedigrees, Exp. Ther. Med., 20, 1237, 10.3892/etm.2020.8829 · DOI
- Jabi, 2014, Subclinical Pheochromocytoma and Paraganglioma in an Elderly Patient: A Case Report, JSM Clin. Rep., 2, 1036
- Brouwers, 2013, Pancreatic cyst development: Insights from von Hippel-Lindau disease, Cilia, 2, 3, 10.1186/2046-2530-2-3 · DOI
- Blansfield, 2007, Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs), Surgery, 142, 814, 10.1016/j.surg.2007.09.012 · doi:10.1016/j.surg.2007.09.012
- Maher, 2011, von Hippel-Lindau disease: A clinical and scientific review, Eur. J. Hum. Genet., 19, 617, 10.1038/ejhg.2010.175 · DOI · Paper page
- Zanoletti, 2017, Endolymphatic sac tumour in von Hippel-Lindau disease: Management strategies, Acta Otorhinolaryngol. Ital., 37, 423, 10.14639/0392-100X-1402 · doi:10.14639/0392-100x-1402
- Butman, 2007, Mechanisms of morbid hearing loss associated with tumors of the endolymphatic sac in von Hippel-Lindau disease, JAMA, 298, 41, 10.1001/jama.298.1.41 · DOI
- Gomella, 2019, Obstructive azoospermia secondary to bilateral epididymal cystadenomas in a patient with von Hippel-Lindau, Urol. Case Rep., 27, 100922, 10.1016/j.eucr.2019.100922 · doi:10.1016/j.eucr.2019.100922
- Papadakis, 2016, Epididymal Cystadenomas in von Hippel-Lindau Disease Showing Increased Activity on 68Ga DOTATATE PET/CT, Clin. Nucl. Med., 41, 781, 10.1097/RLU.0000000000001314 · DOI
- Oliveira, 2020, Tumors of the broad ligament: What and when to suspect such rare location, Radiol. Bras., 53, 349, 10.1590/0100-3984.2019.0073 · doi:10.1590/0100-3984.2019.0073
- Nogales, 2012, An analysis of five clear cell papillary cystadenomas of mesosalpinx and broad ligament: Four associated with von Hippel-Lindau disease and one aggressive sporadic type, Histopathology, 60, 748, 10.1111/j.1365-2559.2011.04151.x · doi:10.1111/j.1365-2559.2011.04151.x
- McDonough, 2006, Cellular oxygen sensing: Crystal structure of hypoxia-inducible factor prolyl hydroxylase (PHD2), Proc. Natl. Acad. Sci. USA, 103, 9814, 10.1073/pnas.0601283103 · DOI · Paper page
- Robb, 2007, Activation of the mTOR signaling pathway in renal clear cell carcinoma, J. Urol., 177, 346, 10.1016/j.juro.2006.08.076 · DOI · Paper page
- Wullschleger, 2006, TOR signaling in growth and metabolism, Cell, 124, 471, 10.1016/j.cell.2006.01.016 · DOI · Paper page
- Zoncu, 2011, mTOR: From growth signal integration to cancer, diabetes and ageing, Nat. Rev. Mol. Cell Biol., 12, 21, 10.1038/nrm3025 · DOI · Paper page
- Gingras, 2001, Regulation of translation initiation by FRAP/mTOR, Genes. Dev., 15, 807, 10.1101/gad.887201 · DOI · Paper page
- Porta, C., Paglino, C., and Mosca, A. (2014). Targeting PI3K/Akt/mTOR Signaling in Cancer. Front. Oncol., 4. · DOI · Paper page
- Kucejova, 2011, Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma, Mol. Cancer Res., 9, 1255, 10.1158/1541-7786.MCR-11-0302 · DOI
- Doan, 2019, HIF-mediated Suppression of DEPTOR Confers Resistance to mTOR Kinase Inhibition in Renal Cancer, iScience, 21, 509, 10.1016/j.isci.2019.10.047 · DOI
- Ganner, A., Gehrke, C., Klein, M., Thegtmeier, L., Matulenski, T., Wingendorf, L., Wang, L., Pilz, F., Greidl, L., and Meid, L. (2021). VHL suppresses RAPTOR and inhibits mTORC1 signaling in clear cell renal cell carcinoma. Sci. Rep., 11. · DOI
- Rini, 2008, Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma, Urol. Oncol., 26, 543, 10.1016/j.urolonc.2008.03.012 · DOI
- Rini, 2009, Resistance to targeted therapy in renal-cell carcinoma, Lancet Oncol., 10, 992, 10.1016/S1470-2045(09)70240-2 · DOI · Paper page
- Bellmunt, 2014, Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: Efficacy and toxicity, Clin. Genitourin. Cancer, 12, 262, 10.1016/j.clgc.2014.03.002 · DOI
- Yao, 2017, VHL Deficiency Drives Enhancer Activation of Oncogenes in Clear Cell Renal Cell Carcinoma, Cancer Discov., 7, 1284, 10.1158/2159-8290.CD-17-0375 · DOI · Paper page
- Zhang, 2018, VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma, Science, 361, 290, 10.1126/science.aap8411 · DOI · Paper page
- Zhu, 2020, ZHX2 drives cell growth and migration via activating MEK/ERK signal and induces Sunitinib resistance by regulating the autophagy in clear cell Renal Cell Carcinoma, Cell Death Dis., 11, 337, 10.1038/s41419-020-2541-x · DOI
- Liu, 2020, Genome-wide Screening Identifies SFMBT1 as an Oncogenic Driver in Cancer with VHL Loss, Mol. Cell, 77, 1294, 10.1016/j.molcel.2020.01.009 · DOI
- Chen, 2021, Novel VHL substrate targets SFMBT1 and ZHX2 may be important prognostic predictors in patients with ccRCC, Oncol. Lett., 21, 379, 10.3892/ol.2021.12640 · DOI
- Tedesco, 2019, von Hippel-Lindau mutants in renal cell carcinoma are regulated by increased expression of RSUME, Cell Death Dis., 10, 266, 10.1038/s41419-019-1507-3 · DOI
- Hu, 2020, TBK1 Is a Synthetic Lethal Target in Cancer with VHL Loss, Cancer Discov., 10, 460, 10.1158/2159-8290.CD-19-0837 · DOI · Paper page
- Kanno, 2020, Role of VHL-JAK-STAT signaling pathway in central nervous system hemangioblastoma associated with von Hippel-Lindau disease, J. Neurooncol., 148, 29, 10.1007/s11060-020-03506-8 · DOI
- Perrotta, 2006, Von Hippel-Lindau-dependent polycythemia is endemic on the island of Ischia: Identification of a novel cluster, Blood, 107, 514, 10.1182/blood-2005-06-2422 · DOI · Paper page
- Bento, 2005, Congenital polycythemia with homozygous and heterozygous mutations of von Hippel-Lindau gene: Five new Caucasian patients, Haematologica, 90, 128
- Gnarra, 1997, Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice, Proc. Natl. Acad. Sci. USA, 94, 9102, 10.1073/pnas.94.17.9102 · DOI · Paper page
- Voest, 2010, von Hippel-Lindau tumor suppressor mutants faithfully model pathological hypoxia-driven angiogenesis and vascular retinopathies in zebrafish, Dis. Model. Mech., 3, 343, 10.1242/dmm.004036 · DOI
- Chew, 2005, Ocular manifestations of von Hippel-Lindau disease: Clinical and genetic investigations, Trans. Am. Ophthalmol. Soc., 103, 495
- Rankin, 2006, Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor, Cancer Res., 66, 2576, 10.1158/0008-5472.CAN-05-3241 · DOI · Paper page
- Ding, 2006, Loss of the tumor suppressor Vhlh leads to upregulation of Cxcr4 and rapidly progressive glomerulonephritis in mice, Nat. Med., 12, 1081, 10.1038/nm1460 · DOI · Paper page
- Shen, H.C., Adem, A., Ylaya, K., Wilson, A., He, M., Lorang, D., Hewitt, S.M., Pechhold, K., Harlan, D.M., and Lubensky, I.A. (2009). Deciphering von Hippel-Lindau (VHL/Vhl)-associated pancreatic manifestations by inactivating Vhl in specific pancreatic cell populations. PLoS ONE, 4. · DOI
- Frew, 2008, Combined VHLH and PTEN mutation causes genital tract cystadenoma and squamous metaplasia, Mol. Cell Biol., 28, 4536, 10.1128/MCB.02132-07 · DOI
- Hong, 2006, Vascular defects and liver damage by the acute inactivation of the VHL gene during mouse embryogenesis, Lab. Investig., 86, 664, 10.1038/labinvest.3700431 · DOI
- Haase, 2001, Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor, Proc. Natl. Acad. Sci. USA, 98, 1583, 10.1073/pnas.98.4.1583 · DOI · Paper page
- Ma, 2003, Hepatic vascular tumors, angiectasis in multiple organs, and impaired spermatogenesis in mice with conditional inactivation of the VHL gene, Cancer Res., 63, 5320
- Park, 2012, Von Hippel-Lindau disease (VHL): A need for a murine model with retinal hemangioblastoma, Histol. Histopathol., 27, 975
- Patard, 2009, Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma, Br. J. Cancer, 101, 1417, 10.1038/sj.bjc.6605298 · DOI · Paper page
- Los, 1997, Elevated ocular levels of vascular endothelial growth factor in patients with von Hippel-Lindau disease, Ann. Oncol., 8, 1015, 10.1023/A:1008213320642 · DOI
- 2017, Prognostic Value of the VHL, HIF-1alpha, and VEGF Signaling Pathway and Associated MAPK (ERK1/2 and ERK5) Pathways in Clear-Cell Renal Cell Carcinoma. A Long-Term Study, Clin. Genitourin. Cancer, 15, e923, 10.1016/j.clgc.2017.05.016 · DOI
- NIH/FDA (2024, August 22). BEST (Biomarkers, EndpointS, and Other Tools) Resource, Available online: https://www.ncbi.nlm.nih.gov/books/NBK326791/.
- Wang, 2017, Shorter telomere length increases age-related tumor risks in von Hippel-Lindau disease patients, Cancer Med., 6, 2131, 10.1002/cam4.1134 · DOI
- Maroto, 2017, HIF pathway and c-Myc as biomarkers for response to sunitinib in metastatic clear-cell renal cell carcinoma, OncoTargets Ther., 10, 4635, 10.2147/OTT.S137677 · DOI
- Qi, 2018, SERPINH1 overexpression in clear cell renal cell carcinoma: Association with poor clinical outcome and its potential as a novel prognostic marker, J. Cell. Mol. Med., 22, 1224, 10.1111/jcmm.13495 · DOI
- Hong, 2019, Differential Expression of PD-L1 between Sporadic and VHL-Associated Hereditary Clear-Cell Renal Cell Carcinoma and Its Correlation with Clinicopathological Features, Clin. Genitourin. Cancer, 17, 97, 10.1016/j.clgc.2018.11.001 · DOI
- Radspieler, 2019, Lamin-B1 is a senescence-associated biomarker in clear-cell renal cell carcinoma, Oncol. Lett., 18, 2654
- Zhang, 2020, Development and validation of a VHL-associated immune prognostic signature for clear cell renal cell carcinoma, Cancer Cell Int., 20, 584, 10.1186/s12935-020-01670-5 · DOI
- Yang, 2021, Identification and validation of the clinical roles of the VHL-related LncRNAs in clear cell renal cell carcinoma, J. Cancer, 12, 2702, 10.7150/jca.55113 · DOI
- Oosting, 2016, 89Zr-Bevacizumab PET Visualizes Disease Manifestations in Patients with von Hippel-Lindau Disease, J. Nucl. Med., 57, 1244, 10.2967/jnumed.115.167643 · doi:10.2967/jnumed.115.167643
- Shell, 2019, The utility of (68)Gallium-DOTATATE PET/CT in the detection of von Hippel-Lindau disease associated tumors, Eur. J. Radiol., 112, 130, 10.1016/j.ejrad.2018.11.023 · doi:10.1016/j.ejrad.2018.11.023
- Xiao, 2021, The prevalence, genetic complexity and population-specific founder effects of human autosomal recessive disorders, NPJ Genom. Med., 6, 41, 10.1038/s41525-021-00203-x · DOI
- McCarthy, 2008, Genome-wide association studies for complex traits: Consensus, uncertainty and challenges, Nat. Rev. Genet., 9, 356, 10.1038/nrg2344 · DOI · Paper page
- Mbemi, A., Khanna, S., Njiki, S., Yedjou, C.G., and Tchounwou, P.B. (2020). Impact of Gene-Environment Interactions on Cancer Development. Int. J. Environ. Res. Public Health, 17. · DOI
- Marmot, 2008, Commission on Social Determinants of H. Closing the gap in a generation: Health equity through action on the social determinants of health, Lancet, 372, 1661, 10.1016/S0140-6736(08)61690-6 · DOI · Paper page
- Knickelbein, 2017, Systemic Sunitinib Malate Treatment for Advanced Juxtapapillary Retinal Hemangioblastomas Associated with von Hippel-Lindau Disease, Ophthalmol. Retina, 1, 181, 10.1016/j.oret.2016.10.007 · DOI
- Jonasch, 2011, Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease, Ann. Oncol., 22, 2661, 10.1093/annonc/mdr011 · DOI
- Hwang, 2021, Intravitreous treatment of severe ocular von Hippel-Lindau disease using a combination of the VEGF inhibitor, ranibizumab, and PDGF inhibitor, E10030: Results from a phase 1/2 clinical trial, Clin. Exp. Ophthalmol., 49, 1048, 10.1111/ceo.14001 · DOI
- Batist, 2002, Neovastat (AE-941) in refractory renal cell carcinoma patients: Report of a phase II trial with two dose levels, Ann. Oncol., 13, 1259, 10.1093/annonc/mdf195 · doi:10.1093/annonc/mdf195
- Escudier, 2007, Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: New paradigm from a large phase III trial with shark cartilage extract AE 941, J. Urol., 178, 1901, 10.1016/j.juro.2007.07.035 · DOI
- Aguirre, 2019, Evaluation of the safety and effectiveness of oral propranolol in patients with von Hippel-Lindau disease and retinal hemangioblastomas: Phase III clinical trial, BMJ Open Ophthalmol., 4, e000203, 10.1136/bmjophth-2018-000203 · DOI
- Panakis, 2008, Sorafenib therapy and CNS hemangioblastomas in individuals with Von Hippel Lindau syndrome, J. Clin. Oncol., 26, 2065, 10.1200/jco.2008.26.15_suppl.2065 · doi:10.1200/jco.2008.26.15_suppl.2065
- Jonasch, 2018, Pazopanib in patients with von Hippel-Lindau disease: A single-arm, single-centre, phase 2 trial, Lancet Oncol., 19, 1351, 10.1016/S1470-2045(18)30487-X · DOI · Paper page
- Hasanov, 2021, MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinoma, Expert. Opin. Investig. Drugs, 30, 495, 10.1080/13543784.2021.1925248 · DOI
- Pilie, 2016, Pilot study of dovitinib in patients with VHL disease, J. Clin. Oncol., 34, 587, 10.1200/jco.2016.34.2_suppl.587 · doi:10.1200/jco.2016.34.2_suppl.587
- Wong, 2008, Intravitreal ranibizumab therapy for retinal capillary hemangioblastoma related to von Hippel-Lindau disease, Ophthalmology, 115, 1957, 10.1016/j.ophtha.2008.04.033 · DOI
- Stamatakis, 2013, Phase II trial of vandetanib in Von Hippel-Lindau-associated renal cell carcinoma, J. Clin. Oncol., 31, 4584, 10.1200/jco.2013.31.15_suppl.4584 · doi:10.1200/jco.2013.31.15_suppl.4584
- Ma, K., Hong, B., Zhou, J., Gong, Y., Wang, J., Liu, S., Peng, X., Zhou, B., Zhang, J., and Xie, H. (2019). The Efficacy and Safety of Tyrosine Kinase Inhibitors for Von Hippel-Lindau Disease: A Retrospective Study of 32 Patients. Front. Oncol., 9. · DOI
- Friedrich, 1999, Von Hippel-Lindau syndrome. A pleomorphic condition, Cancer, 86, 2478, 10.1002/(SICI)1097-0142(19991201)86:11+<2478::AID-CNCR4>3.0.CO;2-5 · DOI · Paper page
- Nagai, 2000, Plasma levels of vascular endothelial growth factor in patients with acromegaly, Horm. Metab. Res., 32, 326, 10.1055/s-2007-978645 · DOI
- Schraml, 2002, VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma, J. Pathol., 196, 186, 10.1002/path.1034 · DOI · Paper page
Cited by
Srinivasan, R., Iliopoulos, O., Beckermann, K. E., Narayan, V., Maughan, B. L., Oudard, S., Else, T., Maranchie, J. K., Iversen, A. B., Cornell, J., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00099-3 · Cited by 50
Metadata
- Authors
- Gómez-Virgilio, L., Velazquez-Paniagua, M., Cuazozon-Ferrer, L., Silva-Lucero, M.-D.-C., Gutierrez-Malacara, A.-I., Padilla-Mendoza, J.-R., Borbolla-Vázquez, J., Díaz-Hernández, J.-A., Jiménez-Orozco, F.-A., & Cardenas-Aguayo, M.-D.-C.
- Venue
- Diagnostics
- Publisher
- MDPI AG
- Published
- 2024-08-29
- Volume
- 14
- Issue
- 17
- Pages
- 1909
- ISSN
- 2075-4418
- Cited by
- 18
- References
- 14
- Language
- en
- Funders
- CONAHCYT, “Ciencia Básica, Ciencia de Frontera Modalidad: Paradigmas y Controversias de la Ciencia 2022” (319578)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Genetics, Pathophysiology, and Current Challenges in Von Hippel–Lindau Disease Therapeutics. https://app.cochat.ai/papers/10.3390/diagnostics14171909
- The paper
- Gómez-Virgilio, L., Velazquez-Paniagua, M., Cuazozon-Ferrer, L., Silva-Lucero, M.-D.-C., Gutierrez-Malacara, A.-I., Padilla-Mendoza, J.-R., Borbolla-Vázquez, J., Díaz-Hernández, J.-A., Jiménez-Orozco, F.-A., & Cardenas-Aguayo, M.-D.-C. (2024). Genetics, Pathophysiology, and Current Challenges in Von Hippel–Lindau Disease Therapeutics. Diagnostics. https://doi.org/10.3390/diagnostics14171909
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.